Gyre Therapeutics (GYRE) investor relations material

Company overview and business model

• Commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases, with operations in the U.S. and China.

• Recently completed an all-stock merger with Cullgen, integrating targeted protein degrader technology and expanding therapeutic areas to include cancer and pain.

• Significant business operations are conducted through subsidiaries in the PRC, exposing the company to unique legal and regulatory risks.

Financial performance and metrics

• Cullgen was valued at approximately $300 million in the merger transaction.

• No recent dividends paid by PRC subsidiaries; future earnings are expected to be retained for business operations.

Use of proceeds and capital allocation

• No proceeds will be received by the company from the resale of shares; all proceeds go to selling stockholders.

• Company will bear registration and listing costs, while selling stockholders cover their own transaction expenses.